Technical Data
044981
KN-93 (water soluble) (2-amino-N-(4-chlorocinnamyl)-N-methylbenzylamine)
1mg
Biochemicals Storage: 4C/-20CShipping: Blue Ice
Selective Ca2+/calmodulin-dependent protein kinase II inhibitor.
Insulin release inhibitor.
Acid secretion inhibitor.
G1 cell cycle arrest inducer.
Apoptosis inducer.
Ion channel inhibitor.
ROS inducer.
Androgen receptor inhibitor.


Storage and Stability:
Short-term Storage: +4C
Long-term Storage: -20C
Stable for at least 2 years after receipt when stored at -20C.

CAS Number:
139298-40-1

Molecular Formula:
C26H29ClN2O4S . H3PO4

Molecular Weight:
501.0+98.0
Purity: >98% (NMR)

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
Product Reference:
The newly synthesized selective Ca2+/calmodulin dependent protein kinase II inhibitor KN-93 reduces dopamine contents in PC12h cells: M. Sumi, et al.; BBRC 181, 968 (1991)
Presence and possible involvement of Ca/calmodulin-dependent protein kinases in insulin release from the rat pancreatic beta cell: I. Niki, et al.; BBRC& 191, 255 (1993)
Inhibition of acid secretion in gastric parietal cells by the Ca2+/calmodulin-dependent protein kinase II inhibitor KN-93: N. Mamiya, et al.; BBRC 195, 608 (1993)
G1 cell cycle arrest and apoptosis are induced in NIH 3T3 cells by KN-93, an inhibitor of CaMK-II (the multifunctional Ca2+/CaM kinase): R.M. Tombes, et al.; Cell Growth Differ. 6, 1063 (1995)
CaMKII-independent effects of KN93 and its inactive analog KN92: reversible inhibition of L-type calcium channels: L. Gao, et al.; BBRC 345, 1606 (2006)
KN-93 (2--N-(4-methoxybenzenesulfonyl)]amino-N-(4-chlorocinnamyl)-N-methylbenzylamine), a calcium/calmodulin-dependent protein kinase II inhibitor, is a direct extracellular blocker of voltage-gated potassium channels: S. Reazadeh, et al.; J. Pharmacol. Exp. Ther. 317, 292 (2006)
KN-93 inhibits androgen receptor activity and induces cell death irrespective of p53 and Akt status in prostate cancer: O.W. Rokhlin, et al.; Cancer Biol. Ther. 9, 224 (2010)


Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.